Double Insurance for OC: MiRNA-Mediated Platinum Resistance and Immune Escape

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Apr 19

PMID 33868274

Citations 5

Authors

Xueqin Zou

Yangjing Zhao

Xiuting Liang

Hui Wang

Yanling Zhu

Qixiang Shao

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC) is still the leading cause of death among all gynecological malignancies, despite the recent progress in cancer therapy. Immune escape and drug resistance, especially platinum-based chemotherapy, are significant factors causing disease progression, recurrence and poor prognosis in OC patients. MicroRNAs(miRNAs) are small noncoding RNAs, regulating gene expression at the transcriptional level. Accumulating evidence have indicated their crucial roles in platinum resistance. Importantly, they also act as mediators of tumor immune escape/evasion. In this review, we summarize the recent study of miRNAs involved in platinum resistance of OC and systematically analyses miRNAs involved in the regulation of OC immune escape. Further understanding of miRNAs roles and their possible mechanisms in platinum resistance and tumor escape may open new avenues for improving OC therapy.

Citing Articles

LINC01119 encapsulated by cancer-associated adipocytes-derived exosomes promotes M2 polarization of macrophages to induce immune escape in ovarian cancer in a 3D co-culture cell-based model.

Zheng Q, Zhang J, Liu Y, Dong W, Dai X, Du X Clin Transl Oncol. 2023; 25(11):3174-3187.

PMID: 37142874 DOI: 10.1007/s12094-023-03185-7.

Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.

Havasi A, Cainap S, Havasi A, Cainap C Medicina (Kaunas). 2023; 59(3).

PMID: 36984544 PMC: 10057458. DOI: 10.3390/medicina59030544.

Overexpression of transmembrane protein 102 implicates poor prognosis and chemoresistance in epithelial ovarian carcinoma patients.

Tai Y, Ou C, Chiang Y, Chang C, Chen C, Cheng W Am J Cancer Res. 2022; 12(9):4211-4226.

PMID: 36225641 PMC: 9548018.

MiR-320b and miR-320d as Biomarkers to Predict and Participate in the Formation of Platinum Resistance in Ovarian Cancer Patients.

Liu Y, Zhao R, Liu C, Zhou J, Yang L, Li L Front Oncol. 2022; 12:881496.

PMID: 35592674 PMC: 9110861. DOI: 10.3389/fonc.2022.881496.

Interaction of Adenosine, Modified Using Carborane Clusters, with Ovarian Cancer Cells: A New Anticancer Approach against Chemoresistance.

Bednarska-Szczepaniak K, Przelazly E, Kania K, Szwed M, Litecka M, Gruner B Cancers (Basel). 2021; 13(15).

PMID: 34359756 PMC: 8345486. DOI: 10.3390/cancers13153855.

References

Srivastava A, Han C, Zhao R, Cui T, Dai Y, Mao C . Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells. Proc Natl Acad Sci U S A. 2015; 112(14):4411-6. PMC: 4394248. DOI: 10.1073/pnas.1421365112. View

Cai Y, Tan X, Liu J, Shen Y, Wu D, Ren M . Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. Chin J Cancer Res. 2014; 26(5):564-72. PMC: 4220257. DOI: 10.3978/j.issn.1000-9604.2014.08.20. View

Li N, Yang L, Wang H, Yi T, Jia X, Chen C . MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells. PLoS One. 2015; 10(6):e0128886. PMC: 4456206. DOI: 10.1371/journal.pone.0128886. View

Sun C, Li N, Yang Z, Zhou B, He Y, Weng D . miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst. 2013; 105(22):1750-8. DOI: 10.1093/jnci/djt302. View

Chen X, Zhang X, Zhang G, Gao Y . Artesunate promotes Th1 differentiation from CD4+ T cells to enhance cell apoptosis in ovarian cancer via miR-142. Braz J Med Biol Res. 2019; 52(5):e7992. PMC: 6489539. DOI: 10.1590/1414-431X20197992. View

Ishida S, Lee J, Thiele D, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22):14298-302. PMC: 137878. DOI: 10.1073/pnas.162491399. View

Vera O, Jimenez J, Pernia O, Rodriguez-Antolin C, Rodriguez C, Sanchez Cabo F . DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through Overexpression in Cancer Cells. Theranostics. 2017; 7(17):4118-4134. PMC: 5695001. DOI: 10.7150/thno.20112. View

He J, Yu J, Xu Q, Wang L, Zheng J, Liu L . Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. Autophagy. 2015; 11(2):373-84. PMC: 4502709. DOI: 10.1080/15548627.2015.1009781. View

Xiao S, Zhang M, Liu C, Wang D . MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer. Mol Genet Genomics. 2018; 293(5):1159-1167. DOI: 10.1007/s00438-018-1447-0. View

10.

Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Fuso Nerini I . Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer. 2012; 49(2):520-30. DOI: 10.1016/j.ejca.2012.06.026. View

11.

Xie J, Liu M, Li Y, Nie Y, Mi Q, Zhao S . Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression. Cell Mol Immunol. 2014; 11(5):495-502. PMC: 4197204. DOI: 10.1038/cmi.2014.30. View

12.

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

13.

Yang-Hartwich Y, Soteras M, Lin Z, Holmberg J, Sumi N, Craveiro V . p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene. 2014; 34(27):3605-16. DOI: 10.1038/onc.2014.296. View

14.

Wang T, Hao D, Yang S, Ma J, Yang W, Zhu Y . miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer. Cell Death Dis. 2019; 10(7):495. PMC: 6591289. DOI: 10.1038/s41419-019-1715-x. View

15.

Rizzo S, Hersey J, Mellor P, Dai W, Santos-Silva A, Liber D . Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther. 2011; 10(2):325-35. PMC: 3037846. DOI: 10.1158/1535-7163.MCT-10-0788. View

16.

Mansouri A, Ridgway L, Korapati A, Zhang Q, Tian L, Wang Y . Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem. 2003; 278(21):19245-56. DOI: 10.1074/jbc.M208134200. View

17.

Sun L, Zhai R, Zhang L, Zhao S . MicroRNA-149 suppresses the proliferation and increases the sensitivity of ovarian cancer cells to cisplatin by targeting X-linked inhibitor of apoptosis. Oncol Lett. 2018; 15(5):7328-7334. PMC: 5920966. DOI: 10.3892/ol.2018.8240. View

18.

Reynolds P, Cooper S, Lomax M, ONeill P . Disruption of PARP1 function inhibits base excision repair of a sub-set of DNA lesions. Nucleic Acids Res. 2015; 43(8):4028-38. PMC: 4417162. DOI: 10.1093/nar/gkv250. View

19.

Liu G, Xue F, Zhang W . miR-506: a regulator of chemo-sensitivity through suppression of the RAD51-homologous recombination axis. Chin J Cancer. 2015; 34(11):485-7. PMC: 4593343. DOI: 10.1186/s40880-015-0049-z. View

20.

Amini-Farsani Z, Sangtarash M, Shamsara M, Teimori H . MiR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway. Cytotechnology. 2017; 70(1):203-213. PMC: 5809651. DOI: 10.1007/s10616-017-0134-z. View